MedTrace Logo

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

NCT02307149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-01-17

No results posted yet for this study

Summary

Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.

Conditions

Interventions

BIOLOGICAL

CAVATAK

CAVATAK is a preparation of CVA21

DRUG

Ipilimumab

Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma

Sponsors & Collaborators

  • Providence Health & Services

    collaborator OTHER

  • Viralytics

    lead INDUSTRY

Principal Investigators

  • Brendan Curti, MD · Providence Health & Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-05
Primary Completion
2019-11-05
Completion
2019-11-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307149 on ClinicalTrials.gov